Lung cancer trials in Italy

In Italy 272 Also abroad 2746

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Milan, Reggio Emilia
Age
18 years to 100 years
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
Phase 2Taking people
Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations
Where
Aviano, Bari, Genoa, Meldola, Monza, Naples, Novara, Parma, Pavia, Perugia, Rionero In Vulture, Rome, Varese
Age
18 years and over
People
35
Run by
Fondazione Ricerca Traslazionale
See details and how to join2025-520676-26-00
Phase 2Completed
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Ancona, Brescia, Candiolo, Milan, Parma, Rome
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Bologna, Milan, Verona
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1Taking people
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Where
Milan, Rozzano, Verona
Age
18 years and over
People
710 worldwide
Run by
Incyte Corporation
See details and how to joinNCT06179160 · EU 2023-507091-47-00
Phase 1Not yet taking people in Italy
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Where
Milan
Age
18 years and over
People
240 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06476808 · EU 2025-523067-38-01
Phase 3Completed
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
Where
Catania, Florence, Meldola, Modena, Naples, Padova, Pavia, Rome
Age
18 years and over
People
147 worldwide
Run by
Shanghai Junshi Biosciences Co. Ltd.
See details and how to join2023-507097-41-01
No phaseTaking people
Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia
Where
Milan
Age
18 years and over
People
120
Run by
Fondazione Don Carlo Gnocchi ETS
See details and how to joinNCT07707245
Phase 1/2Taking people
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Where
Milan, Ravenna, Rossano, Siena
Age
18 years and over
People
180 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00
Phase 2Active, not recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Where
Candiolo, Florence, Milan, Modena, Pavia, Pesaro
Age
18 years to 70 years
People
170 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00
No phaseTaking people
Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
Where
Roma
Age
18 years and over
People
70
Run by
Regina Elena Cancer Institute
See details and how to joinNCT07649629
Phase 1Taking people
THE-0504 in Patients With Solid Tumors
Where
Rome
Age
18 years and over
People
30
Run by
Thena Biotech S.r.l.
See details and how to joinNCT07646106 · EU 2023-503787-17-00
Phase 2/3Not yet taking people in Italy
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
Where
Aviano, Candiolo, Catania, Guastalla, Meldola, Milan, Monza, Naples, Padova, Piacenza, Reggio Emilia, Rome, Rozzano MI, Trento
Age
18 years and over
People
36
Run by
IRCCS Istituto Nazionale Tumori Fondazione Pascale
See details and how to join2025-522084-15-00
No phaseTaking people
Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients
Where
Rome
Age
18 years and over
People
150
Run by
Regina Elena Cancer Institute
See details and how to joinNCT07637474
Phase 2Taking people
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Where
Rome
Age
18 years and over
People
37
Run by
Regina Elena Cancer Institute
See details and how to joinNCT06771518
No phaseTaking people
Standardization of a Platform of Preclinical Models Derived From NSCLC Patients
Where
Rome
Age
18 years and over
People
5
Run by
Regina Elena Cancer Institute
See details and how to joinNCT07629375
Phase 2Not yet taking people in Italy
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
Where
Brescia, Milan, Rome, Udine
Age
18 years and over
People
158 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT07234877 · EU 2025-522985-60-00
Phase 2Not yet taking people in Italy
Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020
Where
Aviano, Bari, Bologna, Camaiore, Catania, Florence, Meldola, Modena, Monza, Naples, Orbassano, Padova, Parma, Perugia, Rome, Rozzano, Verona
Age
18 years and over
People
33
Run by
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
See details and how to join2024-519106-12-00
Phase 2Taking people
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Where
Meldola, Milan, Perugia, Treviso
Age
18 years and over
People
44 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT05718323 · EU 2022-502092-33-00
Phase 1/2Active, not recruiting
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Where
Aviano, Milan, Rome
Age
12 years and over
People
500 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00
Phase 2Not yet taking people in Italy
A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma positive for PD-L1 expression and germline or somatic mutations in the HRR genes
Where
Acquaviva delle Fonti, Aviano, Bari, Catania, Florence, Genoa, Lecce, Meldola, Messina, Monza, Naples, Orbassano, Padova, Pavia, Pesaro, Reggio Emilia, Varese, IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena
Age
18 years and over
People
48
Run by
Universita' Degli Studi Di Torino
See details and how to joinNCT04940637 · EU 2024-515555-38-01
Phase 3Not yet taking people in Italy
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Where
Milan, Naples, Olbia, Orbassano, Rome, Rozzano
Age
18 years and over
People
180 worldwide
Run by
Nuvation Bio Inc.
See details and how to joinNCT07154706 · EU 2025-521971-29-00
Phase 1Taking people
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
Where
Milan, Reggio Emilia
Age
18 years and over
People
76 worldwide
Run by
Novartis Pharma AG
See details and how to join2023-510356-23-00
Phase 3Taking people
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Where
Bari, Meldola, Milan, Reggio Emilia, Roma, Verona
Age
18 years and over
People
170 worldwide
Run by
Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00
Phase 2Not yet taking people in Italy
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Where
Milan, Padova, Rome
Age
18 years and over
People
80 worldwide
Run by
Advenchen Pharmaceuticals, LLC.
See details and how to joinNCT05363280 · EU 2023-509067-24-01